£415 million! Sartorius acquires recombinant albumin company Albumedix
On August 8, the German life sciences group Sartorius announced that through its French-listed subsidiary Sartorius Stedim Biotech, it has agreed to acquire 100% of the shares of Albumedix Ltd. from private investors.
Based in Nottingham, UK, Albumedix is recognized as a global leader in recombinant human albumin products and technologies.
Recombinant human albumin is an essential ingredient for various applications in the biopharmaceutical industry, such as as an animal-free additive for cell culture media and for stabilization of vaccines and viral therapies. Founded in 1984, the company employs more than 100 people and is expected to generate revenue of around £33 million in 2022 with a respectable double-digit EBITDA margin.
The purchase price is approximately £415 million. The transaction is subject to regulatory approval and is expected to close by the end of the third quarter of 2022.
Albumedix will become part of Sartorius’ Bioprocessing Solutions division, and Albumedix’s existing 72,000 sq. ft. site in Nottingham, UK, will be a centre of excellence for innovative and GMP compliant production of critical raw materials.
